ACELYRIN Confirms Indication of Interest from Concentra Biosciences
Deal News | Feb 21, 2025 | Globenewswire
ACELYRIN, a late-stage clinical biopharmaceutical company, has confirmed receipt of an unsolicited acquisition proposal from Concentra Biosciences, with Tang Capital Partners as the controlling shareholder. The offer stands at $3.00 per share in cash, plus a contingent value right. This development comes on the heels of ACELYRIN's recent announcement of an agreement to merge with Alumis Inc. in an all-stock transaction. While the merger with Alumis is slated for closure in the second quarter of 2025 pending shareholder approval, the board of ACELYRIN is currently assessing the offer from Concentra. Throughout this process, ACELYRIN is advised by Guggenheim Securities as financial advisor and is represented legally by Fenwick & West LLP and Paul Hastings LLP. This situation underscores the dynamic nature of corporate transactions in the biopharmaceutical sector, highlighting both the opportunities and strategic challenges faced by companies striving to advance their therapeutic portfolios.
Sectors
- Biopharmaceuticals
- Mergers and Acquisitions
Geography
- United States – The companies involved, ACELYRIN, Alumis, and Concentra Biosciences, are based in the United States, making it the relevant geographical context.
Industry
- Biopharmaceuticals – The article involves ACELYRIN, a biopharma company focusing on immunology treatments, and Concentra Biosciences, indicating activity within the biopharmaceutical industry.
- Mergers and Acquisitions – The article discusses ACELYRIN's merger with Alumis and an acquisition proposal from Concentra Biosciences, highlighting significant M&A activities.
Financials
- $3.00 per share – The offered price per share by Concentra Biosciences to acquire ACELYRIN.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| ACELYRIN, INC. | Target | Company | A late-stage clinical biopharma company focused on immunology medicines development. |
| Concentra Biosciences, LLC | Bidding Company | Company | A biosciences company backed by Tang Capital Partners making an unsolicited bid for ACELYRIN. |
| Tang Capital Partners, LP | Other | Company | Controlling shareholder of Concentra Biosciences. |
| Alumis Inc. | Other | Company | Company ACELYRIN is set to merge with. |
| Guggenheim Securities, LLC | Financial Advisor | Company | Serving as financial advisor to ACELYRIN. |
| Fenwick & West LLP | Legal Advisor | Company | Providing legal counsel to ACELYRIN. |
| Paul Hastings LLP | Legal Advisor | Company | Providing legal counsel to ACELYRIN. |